Exploring your options for Myelodysplastic Syndromes Treatment in India? Ginger Healthcare brings together a carefully chosen panel of reputed hematologists, practising at world-class hospitals accredited by JCI and NABH. Request a free opinion and a cost estimate from any doctor on the list, and our team will guide you through every step of your journey.
Here are the most reputed doctors in India for Myelodysplastic Syndromes Treatment. Each specialist is carefully vetted for their expertise, experience, and patient outcomes.
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Featured
Here are the most reputed hospitals in India for Myelodysplastic Syndromes Treatment. These hospitals are known for advanced infrastructure, international accreditations, and high success rates.
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders in which abnormal stem cells fail to produce enough healthy blood cells, resulting in low red cell, white cell, or platelet counts. MDS ranges from slow-moving, lower-risk disease that can be managed for years with supportive care, to higher-risk forms that behave more aggressively and may progress to acute myeloid leukaemia. Treatment is highly individualised and guided by the patient's risk score (IPSS-R or IPSS-M), genetic subtype, age, and overall fitness. Options span from watchful waiting and blood transfusion support, through growth factors and disease-modifying drug therapy such as hypomethylating agents or lenalidomide, to allogeneic stem cell transplantation — the only currently recognised potentially curative approach.
Regular monitoring of blood counts combined with blood or platelet transfusions and growth factor injections to manage symptoms, used when immediate disease-modifying therapy is not yet required.
Estimated cost: ~$500 – $1,000
Typical tests: Complete blood count (CBC) with differential, Peripheral blood smear review, Serum ferritin and iron studies, Serum erythropoietin level, Kidney function tests (KFT), Liver function tests (LFT), Viral markers (hepatitis B, hepatitis C, HIV) — pre-transfusion screen, Bone marrow aspirate and biopsy (if not done recently or if counts changing). Done in India before admission.
Estimated cost in India: $3,000 – $8,000
Treatment duration in India: ~3 weeks (~7 hospital visit days across the full span)
Monthly injection or infusion cycles of azacitidine or decitabine that reprogram abnormal bone marrow cells — the standard disease-modifying treatment for higher-risk MDS patients who are not proceeding directly to transplant.
Estimated cost: ~$1,000 – $1,500
Typical tests: Complete blood count (CBC) with differential, Bone marrow aspirate and biopsy with morphology, Cytogenetics (conventional karyotype), Next-generation sequencing (NGS) mutation panel, Liver function tests (LFT), Kidney function tests (KFT), Serum ferritin and iron studies, Viral markers (hepatitis B, C, HIV, CMV). Done in India before admission.
Estimated cost in India: $5,000 – $15,000
That works out to roughly $2,000 – $7,000 per cycle across 2 cycles, plus a one-time pre-treatment work-up of about ~$1,000 – $1,500 (done once). Per-cycle figures are approximate — the headline range above covers the full course.
Treatment duration in India: ~8 weeks (2 cycles × 28 days, ~14 hospital visit days)
An oral targeted drug specifically effective in MDS patients whose bone marrow has a deletion on chromosome 5q, capable of reducing transfusion dependence and sometimes restoring near-normal blood counts.
Estimated cost: ~$1,000 – $1,500
Typical tests: Complete blood count (CBC) with differential, Bone marrow aspirate and biopsy, Cytogenetics confirming del(5q) status, NGS mutation panel (SF3B1, TP53, others), Kidney function tests (KFT) — lenalidomide is renally cleared, Liver function tests (LFT), Serum ferritin and iron studies, Pregnancy test (women of childbearing potential — mandatory for lenalidomide). Done in India before admission.
Estimated cost in India: $4,000 – $10,000
Treatment duration in India: ~4 weeks (1 cycle × 28 days, ~5 hospital visit days)
The only treatment currently regarded as potentially curative for MDS — donor stem cells replace the patient's diseased bone marrow after conditioning chemotherapy, suitable for higher-risk or fit patients with a compatible donor.
Estimated cost in India: $20,000 – $45,000
For more details, visit: Bone Marrow Transplant (BMT) →
From your first enquiry to recovery back home — we manage every detail so you can focus on getting better.
Join 5,000+ patients from 40+ countries who chose world-class care at a fraction of the cost.
